Get the Stockscreener App
208.34
5.20%
-11.42
After Hours:
208.37
0.03
+0.01%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $208.34, with a volume of 8.59M.
It is down -5.20% in the last 24 hours and down -8.91% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$219.76
Open:
$218.5
24h Volume:
8.59M
Relative Volume:
1.30
Market Cap:
$368.38B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
88.23
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-8.49%
1M Performance:
-8.91%
6M Performance:
-6.15%
1Y Performance:
-2.58%
1-Day Range:
$207.60
$219.00
1-Week Range:
$207.60
$228.62
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
208.34 | 391.56B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
918.05 | 883.28B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.28 | 586.06B | 94.19B | 26.80B | 19.70B | 11.05 |
|
AZN
Astrazeneca Plc
|
188.42 | 297.77B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
149.81 | 295.52B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AbbVie (ABBV) Stock Drops 5% After FDA Approves J&J’s Competing Psoriasis Drug - CoinCentral
AbbVie (ABBV) Faces New Competition from J&J's Icotyde Approval - GuruFocus
What's Going On With AbbVie Stock Today?AbbVie (NYSE:ABBV) - Benzinga
J&J’s new psoriasis pill to rival AbbVie’s Skyrizi: BNP Paribas - Seeking Alpha
AbbVie (ABBV) slides as investors weigh policy-related pricing risk and recent financing activity - Quiver Quantitative
What triggered AbbVie shares' latest price pullback - Traders Union
AbbVie, Philip Morris among market cap stock movers on Wednesday - Investing.com
Weak momentum, oversold signals: AbbVie stock slides 3.70% - Traders Union
AbbVie Inc Stock (ABBV) Moved Down by 4.60% on Mar 18: A Full Analysis - TradingKey
CollPlant Biotechnologies Launches Redesigned Corporate Website - Benzinga
AbbVie Stock: EPS Set to Jump 45% in 2026 as Skyrizi and Rinvoq Dominate IBD - TIKR.com
AbbVie Inc. $ABBV Shares Sold by Wilmington Savings Fund Society FSB - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Sunbelt Securities Inc. - MarketBeat
Danske Bank A S Invests $279.61 Million in AbbVie Inc. $ABBV - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Has $31.89 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Captrust Financial Advisors Boosts Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Balances False Claims Act Risks With Alloy Antibody Collaboration - simplywall.st
Advisory Services Network LLC Trims Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV): Billionaire Ken Fisher admires this pharma stock - MSN
AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock - Insider Monkey
AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock? - TradingView
Alloy Therapeutics and Abbvie partner on antibody platform - BioWorld MedTech
AbbVie Inc. $ABBV Shares Purchased by Mirabella Financial Services LLP - MarketBeat
Mariner LLC Purchases 175,406 Shares of AbbVie Inc. $ABBV - MarketBeat
US FDA declines to approve Aldeyra's eye disorder drug, shares slump - Reuters
Morse Asset Management Inc Grows Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Stock Holdings Trimmed by Mercer Global Advisors Inc. ADV - MarketBeat
AbbVie price tries to vent off oversold saturationForecast today17-03-2026 - Economies.com
Mirabella Financial Services LLP Buys 19,980 Shares of AbbVie Inc. $ABBV - MarketBeat
Moore Capital Management LP Sells 40,000 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Stock Holdings Decreased by L2 Asset Management LLC - MarketBeat
AbbVie (ABBV) Partners with Alloy Therapeutics for Advanced Anti - GuruFocus
Alloy Therapeutics agreement with AbbVie to develop a new antibody platform - marketscreener.com
Alloy Therapeutics Agreement With AbbVie To Develop A New Antibody Platform - TradingView
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform - Business Wire
Integrated Wealth Concepts LLC Raises Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Bamco Inc. NY Invests $4.86 Million in AbbVie Inc. $ABBV - MarketBeat
William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities - Yahoo Finance
AbbVie (ABBV) Unveils Skin Quality Index Following Comprehensive Study - GuruFocus
AbbVie’s Allergan Aesthetics launches Skin Quality Index - TipRanks
Iron Triangle Partners LP Has $46.38 Million Position in AbbVie Inc. $ABBV - MarketBeat
Allergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index - AbbVie News Center
Hamilton Wealth LLC Makes New $4.92 Million Investment in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Fayez Sarofim & Co - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Focus Partners Wealth - MarketBeat
Fred Alger Management LLC Acquires 54,335 Shares of AbbVie Inc. $ABBV - MarketBeat
Elevation Point Wealth Partners LLC Buys 8,652 Shares of AbbVie Inc. $ABBV - MarketBeat
Brevan Howard Capital Management LP Sells 26,408 Shares of AbbVie Inc. $ABBV - MarketBeat
Assessing AbbVie (ABBV) Valuation After Recent Share Price Weakness - simplywall.st
Is AbbVie Inc. (ABBV) a good stock to buy now? - MSN
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):